Clinical trials: Rituximab
ITP - Immune Thrombocytopenic Purpura, Viral Hepatitis
Viral Hepatitis B and C Infection in Patients With Idiopathic Thrombocytopenic Purpura Treated With Triple Therapy
Aim of the work To estimate frequency of viral HB \& C infection in ITP patients who received triple therapy in comparison with another group treated with steroids only.
- Trial name
- NCT04113915
- Testing
- triple therapy, Steroids
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Safaa AA Khaled
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies
To evaluate the efficacy and safety of rituximab (genetical recombination) intravenously administered to CIDP patients with positive or negative IgG4 autoantibody.
- Trial name
- RECIPE (NCT03864185)
- Testing
- Rituximab (genetical recombination)
- Where
- 4 sites in Japan
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Nagoya University
Non-Hodgkin Lymphoma (NHL)
Response to Influenza Vaccination in Lymphoma Patients Treated With Rituximab
The purpose of this study is to compare the number of responders to vaccination with the influenza virus vaccine at different time points after last dose of rituximab in patients with lymphoma.
- Trial name
- Rituxivac (NCT01707628)
- Testing
- influenza vaccination with influenza vaccine
- Where
- 7 sites in Netherlands
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- St. Antonius Hospital
Rheumatoid Arthritis
The Effect of Rituximab on the Humoral Response to Influenza Vaccine
Rituximab is a genetically engineered chimeric anti-CD20 monoclonal antibody that selectively targets CD20+ B cells and induces a transient depletion of the CD20+ mature B cell subpopulation.The objective of our study was to…
- Trial name
- NCT00466037
- Testing
- Influenza vaccine
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Relapsing Remitting Multiple Sclerosis
Comparative Study of High-Efficacy Disease Modifying Treatment of Relapsing Multiple Sclerosis
The goal of this prospective, multi-center, non-blinded, non-randomized, non-intervention clinical trial is to compare immunologic, virologic and epigenetic factors in patients with active multiple sclerosis in standard 2.line…
- Trial name
- CoSHEDRMS (NCT06159712)
- Testing
- Blood samples
- Where
- Denmark
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
NMO Spectrum Disorder, MRI
Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)
CLUE is a prospective study to assess structural and functional changes of the brain, spinal cord, and optic nerve, as well as the inflammatory environment in patients with neuroinflammatory and demyelinating diseases.
- Conditions
- NMO Spectrum Disorder, MRI, Multiple Sclerosis, MOGAD
- Trial name
- NCT04106830
- Testing
- Intravenous steroid
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Beijing Tiantan Hospital
B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment
RATIONALE: Drugs used in chemotherapy, such as fludarabine phosphate, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00845104
- Testing
- fludarabine phosphate, rituximab, bevacizumab
- Volunteers
- healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Pharmacological Action
Assessment of Rituximab Therapeutic Response Versus Conventional Treatment
Prospective interventional comparative study to compare the efficacy of Rituximab versus Conventional treatment in Refractory Nephrotic Syndrome including patients on triple immunosuppression protocols.
- Trial name
- NCT05553496
- Testing
- Rituximab, Dexamethasone
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Multiple Sclerosis
Safety of Switching From Rituximab to Ocrelizumab in MS Patients
This is a prospective between and within group observational study to determine differences in tolerability, immunogenicity and safety related outcomes for 100 multiple sclerosis (MS) patients who have been administered at least…
- Trial name
- NCT02980042
- Testing
- Ocrelizumab, Rituximab
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Opsoclonus-myoclonus Syndrome
Study of Cytokines in Children With Opsoclonus-Myoclonus Syndrome
The purpose of this study is to determine if cytokines, inflammatory mediators, are increased in spinal fluid and blood, correlate with disease activity, and could serve as biomarkers or therapeutic targets in children with…
- Trial name
- OMS (NCT00806182)
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- National Pediatric Neuroinflammation Organization, Inc.
Hematopoietic Cell Transplantation Recipient, Refractory B-Cell Non-Hodgkin Lymphoma
Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of gemcitabine hydrochloride, clofarabine, and busulfan before donor stem cell transplant and to see how well it works in treating patients with B-cell or T-cell…
- Conditions
- Hematopoietic Cell Transplantation Recipient, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT01701986
- Testing
- Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
PCNSL
Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT
This single-center, open, single-arm study aim to evaluate the efficacy and tolerability of a therapy introducing zanubrutinib on the basis of rituximab and methotrexate (MTX) [or temozolomide (TMZ), if intolerant to MTX] in…
- Trial name
- NCT05896007
- Testing
- Zanubrutinib, Rituximab, Methotrexate
- Where
- China
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Ruijin Hospital
Lymphoma, Follicular
Follow-up Trial of Rituximab Interferon Transplant Trial: Study Drug-Rituximab and Alpha Interferon
A previous phase II trial entitled Treatment of Follicular non-Hodgkin's Lymphoma with High Dose Therapy and Stem Cell Support Followed by Consolidative Immunotherapy with Rituximab and Alpha Interferon was conducted at the…
- Trial name
- NCT03087929
- Testing
- Follow up
- Where
- Canada
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Sunnybrook Health Sciences Centre
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
This randomized phase III trial studies combination chemotherapy with blinatumomab to see how well it works compared to induction chemotherapy alone in treating patients with newly diagnosed breakpoint cluster region (BCR)-c-abl…
- Trial name
- NCT02003222
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Blinatumomab
- Where
- 544 sites in United States, Canada and 2 more
- Volunteers
- 488 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Mantle Cell Lymphoma
Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
To learn if the chemotherapy-free combination of pirtobrutinib (also called LOXO-305) and rituximab can help provide long term remission in low and intermediate risk MCL.
- Trial name
- NCT06263491
- Testing
- Rituximab, Pirtobrutinib
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Primary Sjögren's Syndrome, Xerostomia
Effect of B-cell Depletion in Patients With Primary Sjögren's Syndrome
The primary purpose of the study is to determine whether B-cell depletion with Rituximab has an effect on the oral, ocular and general disease manifestations in patients with primary Sjögren´s syndrome, that is, an effect on the…
- Conditions
- Primary Sjögren's Syndrome, Xerostomia, Hyposalivation, Keratoconjunctivitis Sicca
- Trial name
- NCT00426543
- Testing
- MabThera (rituximab), Rituximab, Mabthera
- Where
- Denmark
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Diffuse Large B-cell Lymphoma
Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL
The purpose of the study is to evaluate feasibility and efficacy of rituximab-bendamustine (R-B)combination in elderly patients affected by diffuse large B-cell lymphoma and defined as frail according to CGA.
- Trial name
- NCT01990144
- Testing
- Bendamustine+Rituximab
- Where
- 52 sites in Italy
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Fondazione Italiana Linfomi - ETS
Lymphocytic Leukemia
This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL)
To compare the efficacy and safety of combination treatment with Genasense, fludarabine, and rituximab versus combination treatment with fludarabine and rituximab in previously untreated subjects with CLL.
- Trial name
- NCT00517218
- Testing
- Genasense® (, oblimersen sodium G3139)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Genta Incorporated
Follicular Non-Hodgkin's Lymphoma
Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma
Recently, the availability of R has substantially changed therapeutic approach to FL patients, since its combination with chemotherapy has improved response rates, progression free survival (PFS) and overall survival (OS).
- Trial name
- NCT02063685
- Testing
- R-CHOP or R-bendamustine, Observation, Maintenance weekly x4
- Where
- 48 sites in Italy
- Volunteers
- 807 people, healthy volunteers welcome
- Sponsor
- Fondazione Italiana Linfomi - ETS
NHL With Hemophagocytic Lymphohistiocytosis
Trial of DA-EPOCH Regimen for NHL With HLH
The major purpose of this clinical study is to assess clinical outcome of dose-adjusted EPOCH regimen for patients with non-Hodgkin's lymphoma(NHL)-associated hemophagocytic lymphohistiocytosis
- Trial name
- NCT01818908
- Testing
- DA-EPOCH
- Where
- 4 sites in China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University